Improvement of overall survival in advanced stage mantle cell lymphoma.

@article{Herrmann2009ImprovementOO,
  title={Improvement of overall survival in advanced stage mantle cell lymphoma.},
  author={Annina Herrmann and Eva Hoster and Thomas Zwingers and Günter Brittinger and Marianne Engelhard and Peter Meusers and Marcel Reiser and Roswitha Forstpointner and Bernd Metzner and Norma Peter and Bernhard W{\"o}rmann and Lorenz H. Tr{\"u}mper and Michael Pfreundschuh and Hermann Einsele and Wolfgang Hiddemann and Michael Unterhalt and Martin Dreyling},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 4},
  pages={
          511-8
        }
}
  • Annina Herrmann, E. Hoster, +14 authors M. Dreyling
  • Published 1 February 2009
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with a poor prognosis. To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004). PATIENTS AND METHODS All patients with the histologically confirmed diagnosis of advanced-stage nonblastoid MCL were eligible. To minimize the potential heterogeneity of… 
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
TLDR
MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report
TLDR
Limited-state MCL showed indolent clinical and low-risk prognostic features and Chemotherapy could be effective for controlling localized MCL lesions, with high complete response rates.
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
TLDR
By a population-based approach, this work was able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice, and rituximab and autologous stem cell transplant were independently associated with improved OS in multivariate analysis.
How I treat mantle cell lymphoma.
TLDR
The prognosis of patients with mantle cell lymphoma (median overall survival, 3-5 years) is poorest among B-cell lymphoma patients, even though a prospectively difficult to identify subgroup can survive for years with little or no treatment.
Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
TLDR
It is found that simplified MIPI was an important prognostic factor in Korean patients with MCL and the use of a rituximab-containing regimen was not associated with OS and EFS.
Progress in mantle-cell lymphoma.
TLDR
Hermann et al provide data vital to the discussion of patient outcomes in MCL, where nearly half of all patients were unable to complete therapy because of toxicity, and the idea that intensive treatment approaches might improve long-term outcomes is supported.
Predictors of Indolent Versus Aggressive Disease Behavior for Patients With Newly Diagnosed Mantle Cell Lymphoma
M comprises less than 10% of all cases of non-Hodgkin lymphoma and has heterogeneous clinical behavior ranging from indolent to very aggressive. The disease is characterized by the presence of
Mantle cell lymphoma epidemiology: a population-based study in France
TLDR
It is confirmed that MCL remains an aggressive NHL with a median overall survival less than 4 years and demonstrates that the use of rituximab in first-line treatment has modified overall survival duration.
How I treat How I treat mantle cell lymphoma
Mantle cell lymphoma is included in the World Health Organization classification as distinct lymphoma subtype characterized by the t(11;14)(q13;q32) translocation, which results in overexpression of
Mantle cell lymphoma.
TLDR
It is critical that patients with a more indolent disease have been reported in whom the initiation of therapy can be delayed without any consequence for the survival, since the optimal approach to the management of MCL is still evolving.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Patterns of survival in mantle cell lymphoma.
TLDR
A survival advantage with anthracycline-containing regimens in some patients with MCL is suggested, however, this benefit was evident only for the patients with favourable International Index prognostic scores who may already have a better prognosis.
Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients.
TLDR
Age, stage and leukaemic disease were significantly associated with TTF, and age, stage, leukaemia disease and lactate dehydrogenase (LDH) with survival, and long-term prognosis is poor in MCL.
Improved survival of follicular lymphoma patients in the United States.
TLDR
The survival of patients with FL in the United States has improved over the last 25 years, and the survival improvement may be a result of the sequential application of effective therapies and improved supportive care.
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
TLDR
In both subtypes, patients with less than two residual lymphoma manifestations in remission experienced a relatively good prognosis with an estimated 5-year survival of greater than 60% for MCL and greater than 75% for FCL.
Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL).
TLDR
The present study confirms the unfavorable clinical course of MCL and the possible need for an alternative therapeutic strategy for this NHL category and indicates the correct identification of M CL at diagnosis appears of relevance.
A predictive model for aggressive non-Hodgkin's lymphoma.
TLDR
The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network
TLDR
Based on this large clinicopathological study of prospective clinical trials, multivariate analysis confirmed the central prognostic role of cell proliferation and its superiority to all other histomorphological and clinical criteria.
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.
TLDR
In patients with indolent or mantle cell lymphoma, R-chemo is superior to chemotherapy alone with respect to overall survival.
Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States.
We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
  • O. Howard, J. Gribben, +4 authors M. Shipp
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Favorable clinical and molecular response rates associated with rituximab and CHOP chemotherapy do not translate into prolonged PFS in MCL, prompting additional consideration of antibody-based in vivo purging in subsequent clinical trials.
...
1
2
3
4
...